What is TearClear?
TearClear is a specialized pharmaceutical enterprise dedicated to revolutionizing the administration of topical medications to the ocular surface. By developing a first-in-class platform designed to capture preservatives before they reach the eye, the company addresses critical challenges in patient safety and treatment compliance. Its lead product candidates, primarily focused on glaucoma, represent a significant shift in how chronic ocular conditions are managed. By prioritizing the elimination of harmful additives, TearClear is positioning itself as a disruptive force in ophthalmology, aiming to improve long-term patient outcomes through superior drug delivery technology.
How much funding has TearClear raised?
TearClear has raised a total of $26.5M across 2 funding rounds:
Series A
$4.5M
Series B
$22M
Series A (2017): $4.5M with participation from Bluestem Capital and Visionary Venture Fund
Series B (2020): $22M led by Falcon Vision, Bluestem Capital Company, Visionary Ventures, and Flying L Partners
Key Investors in TearClear
Bluestem Capital
A venture capital firm based in South Dakota that focuses on private equity investments, providing a platform for regional economic growth and supporting promising ventures.
Visionary Ventures
An Orange County-based venture capital firm specializing in life sciences and ophthalmology, leveraging a network of industry experts to identify and fund companies addressing significant unmet medical needs.
Falcon Vision
An institutional investor participating in the funding round, focused on supporting high-growth potential companies within the medical technology and pharmaceutical sectors.
What's next for TearClear?
Following this major strategic investment, TearClear is well-positioned to transition from its current development phase toward broader clinical validation and commercial readiness. The capital infusion will likely be directed toward scaling its manufacturing capabilities and advancing its pipeline of glaucoma-focused therapies. As the company continues to refine its platform, it remains focused on addressing unmet medical needs in the ophthalmic space. Future growth will likely hinge on the successful execution of its clinical trials and the potential for expanding its delivery technology to address additional ocular indications, further solidifying its role as a key innovator in the life sciences sector.
See full TearClear company page
